Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark

Key Takeaways KRYS Q4 EPS of $1.70 topped estimates, as Vyjuvek revenues rose 17.5% year over year.KRYS secured 660 U.S. reimbursements for Vyjuvek and expanded launches across Germany, France and Japan.KRYS advances KB407, KB707 and other candidates, with multiple data readouts and studies slated for 2026.Krystal Biotech (KRYS) reported fourth-quarter 2025 earnings per share (EPS) of $1.70, which surpassed the Zacks Consensus Estimate of $1.62. The reported EPS was up from $1.52 in the year-ago quarter.Rev ...